MIB Agents OsteoBites and osTEAo cover art

All Episodes

MIB Agents OsteoBites and osTEAo — 218 episodes

#
Title
1

osTEAo: Advocacy Doesn't End at Discharge

2

Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma

3

A Guide to FACTOR 2026 Scientific Panels

4

osTEAo - More Than Physical: The Mental Toll of Cancer

5

A Phase 1/2, Study to Evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in Patients with Relapsed/Refractory Osteosarcoma

6

Defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma

7

osTEAo: The Sound of Strength

8

Zanzalintinib in Osteosarcoma: Balancing Disease Control and Quality of Life

9

Extracellular Matrix Degradation to Overcome Osteosarcoma Chemoresistance

10

Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma

11

Identifying mechanisms of chemoresistance in metastatic osteosarcoma using molecular barcoding

12

New insights into shared molecular and genomic features between humans and dogs with OS

13

Implementing personalized, adaptive therapies in osteosarcoma

14

osTEAo: The Sibling Side of Cancer

15

High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches

16

osTEAo: New Year, Same Cancer

17

Next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma

18

Insights from the Musculoskeletal Tumor Society (MSTS) December 2025 Annual Meeting

19

Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma

20

Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution

21

osTEAo: Navigating Loss in the AYA Community

22

Synergy of ATM and PARP Inhibitors in Pediatric Osteosarcoma

23

Comparative extracellular vesicle (EV) biomarkers for osteosarcoma risk and prognosis

24

osTEAo - Spooky Sarcoma Stories

25

Insights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer

26

Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma

27

osTEAo - Turning Pain Into Purpose

28

Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes

29

Deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma

30

osTEAo: The Fault in Our Scars - Dating & Cancer

31

Clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group

32

Simultaneous targeting of CDK4/6 and BETs is independent of RB status in osteosarcoma

33

osTEAo: When Positivity Silences Pain

34

Old drugs, new tricks? A novel immunomodulatory approach to relapsed osteosarcoma therapy

35

Molecular subtyping of osteosarcoma, ecDNA and more

36

osTEAo: What to Expect When You're Not Expecting

37

A Guide to the FACTOR 2025 Scientific Panels with Matteo Trucco, MD

38

Autologous Cancer Vaccine with Checkpoint Inhibitor for Treatment of Canine Osteosarcoma

39

Stuck on the Sidelines: AYA Cancer & FOMO

40

Surgical Options and Advances in Osteosarcoma (La Cirugía de Salvamento de Extremidades)

41

Advocating for Cures: How You Can Support the Give Kids a Chance Act and Advance Pediatric Cancer Research

42

Tumor cGAS-STING repression drives immune evasion in osteosarcoma and is therapeutically targetable via host STING activation

43

osTEAo: Accessibility Wins, Fails & WTF Moments

44

Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: Consensus Recommendations from the Children’s Oncology Group Bone Tumour Committee

45

Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis

46

Multi-modal omics analysis identifies targetable sensory neuron circuitry that promotes sarcoma disease progression

47

osTEAo: Paws and Reflect: How Pets Help Us Heal

48

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma (PREMOST)

49

Minimally Invasive Metastasectomy in Canines (MIMIC)

50

Live-cell whole tissue models reveal sources of dynamic signaling heterogeneity and single cell drug response variation in the metastatic niche

51

osTEAo: Cancer Fatigue: How to Escape the Cancerverse

52

COG Blueprint for Research on Bone Tumors

53

Understanding Tumor Evolution in Osteosarcoma

54

Macrophage engineered vesicles to treat pediatric Osteosarcoma.

55

osTEAo: Hospital Holidays

56

Repurposing Virus Specific T cells as Immune Therapy for Osteosarcoma

57

Repurposing Drugs for Osteosarcoma

58

The ablative and immunomodulatory effects of histotripsy treatment in osteosarcoma

59

osTEAo: Spooky Sarcoma Stories

60

Molecular and cellular deconstruction of metastatic osteosarcoma

61

osTEAo: Back to School: Cancer + Curriculum

62

Fit for Filing Academic Clinical Trials: An Industry Perspective

63

Magnetic Resonance Guided (MRg) High Intensity Focused Ultrasound (HIFU) For Palliation of Canine Appendicular Osteosarcoma

64

osTEAo - Clear Scans…So Now What?

65

Clinical Utility of Functional Precision Medicine to Guide Treatments for Osteosarcoma Patients

66

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

67

A Multi-Institution Study in Combination with Relapsed or Refractory Pediatric Bone and Soft Tissue

68

osTEAo: The Sibling Situation

69

Genomes, Avatars and AI: The Future of Personalized Medicine

70

Exploring Novel Immunotherapies for Canine Osteosarcoma

71

A Guide to the FACTOR 2024 Scientific Panels with Matteo Trucco, MD

72

osTEAo: Long Term Side Effects from Treatment For Osteosarcoma and AYA Cancer

73

Creating a translational genomic framework for canine osteosarcoma: updates on the NCI DOG2 project

74

Positioning Poly-(ADP)-ribose polymerase inhibitors (PARPi) for the treatment of Osteosarcoma

75

TGF-beta inhibition as a novel therapeutic option in Osteosarcoma

76

Out on a Limb - Travel Tips for AYA Cancer Patients

77

Phase 1 Study of Cabozantinib in Combination with Topotecan-Cyclophosphamide for Patients with Relapsed or Refractory Ewing Sarcoma or Osteosarcoma

78

Targeting Urea Cycle Dysfunction to Prevent and Treat Osteosarcoma Metastasis

79

osTEAo: Patient Experiences with Lung Surgery for Osteosarcoma

80

Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research

81

Patient perspectives on participating in research and clinical trials

82

Tissue Engineering Strategies for Elucidating Osteosarcoma Biology and Drug Discovery

83

Liquid biopsy in Ewing sarcoma and osteosarcoma as a prognostic and response diagnostic: The LEOPARD Study

84

Managing Stress in AYA Cancer Patients

85

Prevention of Cisplatin-induced Hearing Loss: Implications for Young People Treated for Osteosarcoma

86

TACOS: A Phase 2 Trial of Atezolizumab and Cabozantinib in OsteoSarcoma

87

osTEAo: Making friends after a cancer diagnosis

88

Interventions to promote physical function during and after treatment for osteosarcoma

89

The Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan (CAUSAL) study

90

Developing a Multiscale Transcriptional Atlas of Sarcoma

91

Immunological Mechanisms of Cancer Defense

92

osTEAo: Long Term Osteosarcoma Survivors: Where They Were and Where They Are Now

93

Cabozantinib as a Maintenance Therapy to Prevent Recurrence of High-Risk Pediatric Solid Tumors

94

osTEAo - Coping with Cancer through Music

95

OsteoBites Preguntas & Respuestas con Nino Rainusso, MD

96

TCF-001 TRACK (Target Rare Cancer Knowledge): A Clinical Trial Studying Precision Medicine in Rare Cancers

97

Repurposing Disulfiram to Overcome Chemotherapy Resistance in Relapsed Sarcomas

98

osTEAo Tea Spill: AYA Cancer Gab Sesh

99

Addressing the Unmet Scientific Challenges in Osteosarcoma Treatment through Innovative Engineering Techniques

100

Implementing Multi-Targeted Tyrosine Kinase Inhibitors in Combination with Chemotherapy for Osteosarcoma

101

Immune Therapies in EGFR-Expressing Cancers

102

OsTEAo - An Honest Q&A with Osteosarcoma AYA Patients, Survivors, and Siblings

103

Treatment of Osteosarcoma Using Smart Targeted Drug Delivery Nanoplatforms

104

MIB Agents and SARC: A Case Study in Collaboration

105

OSI Funded Work

106

OsTEAo - Survivor's Guilt and Grief with grief coach Lori Krause

107

Pretargeted Approach to Delivery of Radiopharmaceutical Therapy for Bone Cancer - a Click Chemistry Study in Canines with Osteosarcoma

108

osTEAo - Coping with Humor: A Review of Cancer Memes

109

The Importance of Patient-Powered Osteosarcoma Research: Count Me In 

110

Osteosarcoma Organoid Models: The Potential and Limitations of Personalized Avatars

111

Reprogramming NK Cells Within the Tumor Microenvironment of Osteosarcoma Lung Metastases

112

osTEAo- Returning to Yourself: Confidence and Identity as an AYA Cancer Patient

113

OSI Connect: Osteosarcoma Answers and Assistance

114

Open Clinical Trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

115

SCF-Skp2 Protein Complex as a Therapy for Osteosarcoma by Blocking the Mutational Effects of Rb and p53

116

osTEAo - Navigating Scanxiety

117

Cold Atmospheric Plasma: A New Therapeutical Option for Osteosarcoma?

118

UHRF1 Overexpression Promotes Osteosarcoma Metastasis through Altered Exosome Production and AMPK/SEMA3E Suppression

119

Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) for Sarcoma

120

osTEAo - Navigating Campus: Limb-Salvage and Amputation Patient Perspectives

121

Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks

122

SarcoSIGHT- A Randomised Controlled Trial of Fluorescence Guided Sarcoma Surgery versus Standard Care

123

Virtual Surgical Planning and 3D Printing in Pediatric Musculoskeletal Oncological Resections

124

Two Epigenetically Distinct Cellular States in Osteo are Regulated by a State-Specific Set of Transcription Factors Driving Differential Drug Response

125

Clinical Trial: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

126

Cell Based Therapies for Osteosarcoma

127

osTEAo Q&A with Dr. Kurt Weiss - What questions do you have about Osteosarcoma but are afraid to ask?

128

Interventional Radiology/HIFU Perspectives for Osteosarcoma

129

Focal Adhesion Kinase (FAK) Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteosarcoma

130

Updates from Clinical Sequencing of 2,138 Bone and Soft Tissue Sarcomas

131

osTEAo Presents Halloween Spooky Stories

132

How Osteosarcoma Evolves from Diagnosis to Relapse

133

Transforming the Way Researchers Share Data: Lessons from the Pediatric Cancer Data Commons

134

osTEAo - Dating & Intimacy with Lauren Broschak, MSW, LCSW, OSW-C

135

Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma

136

Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

137

Inhaled Recombinant Human IL-15 in Dogs with Naturally Occurring Pulmonary Metastases from Osteosarcoma or Melanoma: a Phase 1 Study

138

Outsmarting OS 2021 Funded Research Update: Exploring Aldehyde Dehydrogenase and Androgen Receptor Actions to OutSmart Osteosarcoma Metastases

139

Back to School: OsteoWarrior and OsteoSibling Perspectives

140

Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma

141

Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma

142

COG Project: Every Child - Episode Sponsored by Osteosarcoma Institute

143

Body Image for AYAs with Cancer with Dr. Lori Weiner

144

Unanswered Clinical Questions in Sarcoma: Opportunities to Move from Bedside to Bench - Episode Sponsored by Osteosarcoma Institute

145

Molecular Profiling Identifies Targeted Therapy Opportunities in Pediatric Solid Cancer - Episode Sponsored by Osteosarcoma Institute

146

Navigating Pediatric Cancer Clinical Trials

147

Update on OSI funded phase 2 Trial of Olaparib + Ceralasertib in Recurrent Osteosarcoma

148

Limb Salvage Surgery for OS: Patient & Surgeon Perspectives sponsored by the Osteosarcoma Institute

149

"Armored" CAR T cells for Osteosarcoma sponsored by BTG Specialty Pharmaceuticals

150

Immunotherapy for Osteosarcoma - Where Do We Go From Here? Sponsored by BTG Specialty Pharmaceuticals

151

The Osteosarcoma Project sponsored by BTG Specialty Pharmaceuticals

152

osTEAo Debut

153

Update on Clinical Trial Development Targeting Tumor Microenvironment in Refractory and Metastatic Osteosarcoma

154

Exploring the Use of a Predictive Tool for Methotrexate Clearance sponsored by BTG Specialty Pharmaceuticals

155

A Phase 1/2 Study of ZN-c3 Plus Gemcitabine in Relapsed or Refractory Osteosarcoma

156

MYC Amplification as a Prognostic Biomarker in Osteosarcoma Sponsored by BTG Speciality Pharmaceuticals

157

Compassionate Use of Investigational Drugs: A Strategy to Access Unapproved Therapies for Pediatric Oncology Patients Presented by BTG Speciality Pharmaceuticals

158

The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) International Randomized Controlled Trial Sponsored by BTG Specialty Pharmaceuticals

159

Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals

160

Truths & Myths of Nutrition in Cancer sponsored by BTG Specialty Pharmaceuticals

161

Amputation for OS; Patient & Surgeon Perspectives sponsored by BTG Speciality Pharmaceuticals

162

Surgical Management of Pulmonary Metastases in People with Osteosarcoma - COG Trial

163

Human Trial for OST-HER2

164

Osteosarcoma Q&A with Dr. Peter Anderson and OsteoWarriors

165

Osteobites: Back to Activity, Rotationplasty

166

OsteoBites: Clinical Trials for Relapsed or Refractory Osteosarcoma - The OLIE Study and Beyond!

167

Encore, Testing & Research Directory

168

Real Talk: What it's really like and how WE feel about Osteosarcoma.

169

Planning for Dignity and What Matters Most to You

170

Let's Talk Fertility and Osteosarcoma

171

How "Hydroxychloroquine and "self-eating" works with Osteosarcoma.

172

Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient

173

OsteoBites Welcomes Junior Board Members to discuss "Four OsteoWarriors' Perspectives".

174

OsteoBites welcomes Dr. Moyez Jiwa to discuss "The Art of Doctoring"

175

Osteosarcoma OsteoBites S2 Ep 18: Richard Gorlick, MD & Yifei Wang, MD “Antibody Drug Conjugates for Osteosarcoma”

176

Osteosarcoma OsteoBites S2 Ep 17: Lara Davis, MD, OHSU Knight Cancer Institute “New Osteosarcoma Clinical Trials”

177

Osteosarcoma OsteoBites S2 Ep 16: Julie Lanford, MPH, RD, CSO, LDN on “Nutrition & Cancer; Truths & Myths”

178

Osteosarcoma OsteoBites S2 Ep 15: Katie Greenzang, MD, EdM Dana-Farber CI & Harvard Med School “What’s Next? Survivorship"

179

Osteosarcoma OsteoBites S2 Ep 14: Lillian Guenther, MD Dana-Farber CI & Harvard Med School “CRISPR Screening to Identify Novel Genomic Targets"

180

Osteosarcoma OsteoBites S2 E13: Scott Sauer, PhD on “Preventing Osteosarcoma Lethal Recurrence by Targeting Disseminated Tumor Cells”

181

Osteosarcoma OsteoBites S2 Ep12: Dan Prince, MD, MPH on “Regenerative Surgery for Bone Sarcomas”

182

Osteosarcoma OsteoBites S2 Ep 11: Ines Lohse, PhD on “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”

183

Osteosarcoma OsteoBites S2 Ep 10: Sumit Gupta, MD, PhD, FRCPC “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”

184

MIB Agents OsteoBites S2 Ep 9: Jane Yanagawa, MD, “Osteosarcoma Lung Metastases”

185

OsteoBites S2 Ep 8: Chand Khanna DVM, PhD, “A Comparative Approach To Metastasis: Biology and Therapy”

186

OsteoBites S2 Ep7: Corrie Painter, PhD “The Osteosarcoma Project, Patient-Partnered Research Update”

187

OsteoBites S2 Ep6: Brian Van Tine, MD, PhD on “Osteosarcoma Tumor Metabolism”

188

OsteoBites S2 Ep5: Robbie Majzner, MD on “Unleashing the Pediatric Immune System Against Osteosarcoma and Other Solid Tumors”

189

OsteoBites S3 Ep4: Lor Randall, MD, "Sarcomatology: A Trans-Disciplinary Approach"

190

OsteoBites S2 Ep3: Pete Anderson, MD, PhD "Understanding Lab, Path and Scan Reports and Other Questions Answered"

191

OsteoBites S2 Ep2: Alejandro Sweet Cordero, MD "Genome-Informed Targeted Therapies for Osteosarcoma"

192

OsteoBites S2 Ep1: Erin Murphy, Associate Professor, Radiation Oncology at Cleveland Clinic: Radiosurgery and SBRT for Sarcoma”

193

OsteoBites S1 Ep28: Ryan Roberts, MD, PhD. “Dear Lungs, Stop enabling this cancer: Targeting interactions that facilitate osteosarcoma metastasis.”

194

OsteoBites S1 Ep27: Brian Crompton, MD, “New Genomic Approaches to Understanding Osteosarcoma”

195

OsteoBites S1 Ep25: Sulagna Banerjee, PhD, “Modeling Osteosarcoma in Mice”

196

OsteoBites S1 Ep24: Andy Woods & Charles Keller, MD: "Legacy Autopsy”

197

Lauren: Osteosarcoma Survivor, Sibling of OsteoAngel and MIB Jr. Board Member

198

OsteoBites S1 Ep23: Brian Flesner, DVM, MS, DACVIM: "Adjuvant Chemotherapy for Canine Osteosarcoma ”

199

OsteoBites S1 Ep22: Reed: "Moffitt Osteosarcoma Research Approach”

200

OsteoBites S1 Ep21: Kurt Weiss, MD, A Day In the Life of a Musculoskeletal Oncologist

201

OsteoBites S1 Ep20: Correlative Science Leading to Active and Emerging Clinical Trials for #Osteosarcoma

202

OsteoBites S1 Ep19: Modeling & Targeting MYC-Driven Osteosarcoma

203

OsteoBites S1 Ep18: Coping Through Cancer: Tips for Parents & Caregivers

204

OsteoBites S1 Ep17: The #Osteosarcoma Patient Decision Aid for Surgical Options in the Lower Extremity

205

OsteoBites S1 Ep16: Peter Anderson, MD, PhD on Making It Better for OS Patients

206

OsteoBites S1 Ep15: Survivorship Care Planning with David Poplack, MD and Ellen Shohet, RN

207

OsteoBites S1 Ep14 Katie Janeway, MD, NEW Osteosarcoma Clinical Trial

208

OsteoBites S1 Ep12: John Healey, MD, Precision Surgery for Osteosarcoma

209

OsteoBites S1 Ep11: Alanna Church, MD and Christina Ip-Toma, MIB Testing & Research Directory

210

OsteoBites S1 Ep10: Simon Holland and Elly App

211

OsteoBites S1 Ep9: Amputee Coalition

212

OsteoBites S1 Ep8: Osteosarcoma Research, Joshua Schiffman, MD

213

OsteoBites S1 Ep7: Osteosarcoma Research, Matteo Trucco, MD

214

OsteoBites S1 Ep6: Osteosarcoma Research, J. Andrew Livingston, MD

215

OsteoBites S1 Ep5: Osteosarcoma Research, Alex Huang, MD, PhD of UH Rainbow Babies & Children's & CWRU

216

OsteoBites S1 EP2: Osteosarcoma Q&A with Matteo Trucco, MD of Cleveland Clinic

217

OsteoBites S1 Ep4: Upfront Surgery for Osteosarcoma, David Loeb, MD, PhD & Matteo Trucco, MD

218

OsteoBites: S1, EP3 Osteosarcoma Institute with Lee Helman, MD & Joyce Schaffer, RN